Globeflex Capital L P boosted its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 11.6% in the second quarter, according to its most recent disclosure with the SEC. The firm owned 43,844 shares of the medical research company’s stock after acquiring an additional 4,558 shares during the period. Charles River Laboratories International comprises about 1.1% of Globeflex Capital L P’s holdings, making the stock its 5th biggest holding. Globeflex Capital L P owned 0.09% of Charles River Laboratories International worth $4,435,000 as of its most recent filing with the SEC.

A number of other large investors also recently bought and sold shares of the business. Nordea Investment Management AB raised its position in Charles River Laboratories International by 2.4% during the second quarter. Nordea Investment Management AB now owns 78,970 shares of the medical research company’s stock worth $7,988,000 after acquiring an additional 1,878 shares during the period. M&T Bank Corp raised its position in Charles River Laboratories International by 1.8% during the second quarter. M&T Bank Corp now owns 4,358 shares of the medical research company’s stock worth $441,000 after acquiring an additional 76 shares during the period. California Public Employees Retirement System raised its position in Charles River Laboratories International by 2.1% during the second quarter. California Public Employees Retirement System now owns 68,100 shares of the medical research company’s stock worth $6,888,000 after acquiring an additional 1,400 shares during the period. FIL Ltd raised its position in Charles River Laboratories International by 325.4% during the second quarter. FIL Ltd now owns 417,465 shares of the medical research company’s stock worth $42,227,000 after acquiring an additional 319,324 shares during the period. Finally, FMR LLC raised its position in Charles River Laboratories International by 23.8% during the second quarter. FMR LLC now owns 3,079,179 shares of the medical research company’s stock worth $311,458,000 after acquiring an additional 591,066 shares during the period. Institutional investors own 95.37% of the company’s stock.

Shares of Charles River Laboratories International, Inc. (NYSE CRL) traded up 0.12% during midday trading on Friday, hitting $105.51. 428,696 shares of the stock were exchanged. Charles River Laboratories International, Inc. has a 12-month low of $67.20 and a 12-month high of $109.59. The firm has a market cap of $5.02 billion, a PE ratio of 27.80 and a beta of 0.99. The firm has a 50-day moving average price of $103.50 and a 200 day moving average price of $95.67.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings results on Wednesday, August 9th. The medical research company reported $1.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.22 by $0.07. The business had revenue of $469.13 million during the quarter, compared to the consensus estimate of $458.25 million. Charles River Laboratories International had a return on equity of 27.02% and a net margin of 10.13%. The business’s revenue was up 8.1% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.20 EPS. Analysts predict that Charles River Laboratories International, Inc. will post $5.10 earnings per share for the current fiscal year.

CRL has been the subject of a number of research analyst reports. Zacks Investment Research cut shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a research report on Tuesday, July 25th. Citigroup Inc. restated a “neutral” rating and set a $104.00 price objective (up from $91.00) on shares of Charles River Laboratories International in a research report on Wednesday, June 28th. Robert W. Baird reiterated a “buy” rating and issued a $114.00 target price on shares of Charles River Laboratories International in a research report on Friday, September 1st. BidaskClub cut shares of Charles River Laboratories International from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 31st. Finally, Credit Suisse Group reiterated a “neutral” rating and issued a $95.00 target price (up from $89.00) on shares of Charles River Laboratories International in a research report on Tuesday, June 6th. Six analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $99.59.

ILLEGAL ACTIVITY NOTICE: This report was first posted by Watch List News and is the property of of Watch List News. If you are accessing this report on another publication, it was stolen and reposted in violation of U.S. & international copyright laws. The correct version of this report can be read at https://www.watchlistnews.com/globeflex-capital-l-p-boosts-holdings-in-charles-river-laboratories-international-inc-crl/1583196.html.

In related news, insider David Ross Smith sold 2,552 shares of the business’s stock in a transaction dated Monday, August 14th. The shares were sold at an average price of $67.10, for a total value of $171,239.20. Following the completion of the transaction, the insider now owns 11,671 shares of the company’s stock, valued at approximately $783,124.10. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Davide Molho sold 5,982 shares of the business’s stock in a transaction dated Tuesday, September 5th. The shares were sold at an average price of $107.55, for a total transaction of $643,364.10. Following the completion of the transaction, the insider now directly owns 22,714 shares of the company’s stock, valued at approximately $2,442,890.70. The disclosure for this sale can be found here. Insiders have sold a total of 25,880 shares of company stock valued at $2,541,668 in the last ninety days. Corporate insiders own 2.20% of the company’s stock.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories International, Inc. (NYSE:CRL).

Institutional Ownership by Quarter for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.